Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:289
Structure:
Synonyms:
1,2-benzenediol
1,2-dihydroxybenzene
1,3-dihydroxybenzene
120-80-9
12385-08-9
135011_SIAL
16474-89-8
16474-90-1
2-(5,8-Dihydroxy-1-methoxy-3-methyl(2-naphthyl))-5-methoxy-7-methylnaphthalene-1,4-diol
2-hydroxyphenol
20244-21-7
20244-21-7 (unspecified hydrochloride salt)
37349-32-9
4-06-00-05557 (Beilstein Handbook Reference)
430749_ALDRICH
430749_SIAL
AB-131/40235236
AB1002105
AC1L18WM
AC1Q78GA
AG-D-45381
AI3-03995
AIDS-108194
AIDS108194
AKOS000119002
alpha-hydroxyphenol
BBL002408
BB_NC-2239
Benzcatechin
Benzene, o-dihydroxy-
benzene-1,2-diol
benzenediol
BIDD:ER0327
bmse000385
Brenzcatechin
BRN 0471401
C 9510
C.I. 76500
C.I. Oxidation Base 26
C00090
c0097
C01785
C034221
C15571
C3561_SIAL
C9510_SIAL
C9593_SIGMA
CAQ
Catechin
Catechin (phenol)
CATECHOL
Catechol (phenol)
catechol dipotassium salt
catechol sodium salt
catechol, 14C-labeled cpd
Catechol-pyrocatechol
Catechol-UL-14C
CCG-204375
CCRIS 741
CHEBI:18135
CHEMBL280998
CI 76500
CI Oxidation Base 26
DB02232
Dihydroxybenzene
Durafur developer C
Durafur Developer CFouramine PCH
EINECS 204-427-5
EU-0100280
Fouramine PCH
Fourrine 68
HMS2233A17
HMS3260H22
HSDB 1436
I01-2906
Katechol
Katechol [Czech]
Lopac-C-9510
Lopac0_000280
LS-637
MLS002153385
MLS002303022
MolPort-000-871-939
NCGC00015283-01
NCGC00015283-02
NCGC00015283-03
NCGC00015283-04
NCGC00015283-05
NCGC00015283-06
NCGC00015283-07
NCGC00015283-08
NCGC00091262-01
NCGC00091262-02
NCGC00091262-03
nchembio801-comp10
NCI-C55856
NSC 1573
NSC1573
o Dihydroxybenzene
o-Benzenediol
o-Dihydroxybenzene
o-Dioxybenzene
o-Diphenol
o-Hydroquinone
o-Hydroxyphenol
o-Phenylenediol
ortho-Benzenediol
ortho-Dihydroxybenzene
ortho-Dioxybenzene
ortho-Hydroquinone
ortho-Hydroxyphenol
ortho-Phenylenediol
Oxyphenic acid
P0317
P0567
Pelagol Grey C
phenol derivative, 2
Phthalhydroquinone
pyrocatechin
Pyrocatechine
Pyrocatechinic acid
Pyrocatechinic acidPyrocatechol
pyrocatechol
pyrocatechol-ul-14C
Pyrocatechuic acid
Pyrokatechin
Pyrokatechin [Czech]
Pyrokatechol
Pyrokatechol [Czech]
SMR000326660
ST5214346
STK398651
WLN: QR BQ
ZINC13512214

Target

show target details
Uniprot ID:FAK1_HUMAN
Synonyms:
FADK 1
Focal adhesion kinase 1
pp125FAK
Protein-tyrosine kinase 2
EC-Numbers:2.7.10.2
Organism:Homo sapiens
Human
PDB IDs:1K04 1K05 1MP8 1OW6 1OW7 1OW8 2ETM 2IJM 2RA7 3B71 3BZ3
Structure:
3BZ3

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

19105967
Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7.. Triparna Sen; Shuvojit Moulik; Anindita Dutta; Paromita Roy Choudhury; Aniruddha Banerji; Shamik Das; Madhumita Roy; Amitava Chatterjee (2009) Life sciences display abstract
AIMS: The tumor inhibiting property of green tea polyphenol epigallocatechin-3-gallate (EGCG) is well documented. Studies reveal that matrix-metalloproteinases (MMPs) play pivotal roles in tumor invasion through degradation of basement membranes and extracellular matrix (ECM). We studied the effect of EGCG on matrixmetalloproteinases-2 (MMP-2), the factors involved in activation, secretion and signaling molecules that might be involved in the regulation of MMP-2 in human breast cancer cell line, MCF-7. MAIN METHODS: MCF-7 was treated with EGCG (20 muM, 24 h), the effect of EGCG on MMP-2 expression, activity and its regulatory molecules were studied by gelatin zymography, Western blot, quantitative and semi-quantitative real time RT-PCR, immunoflourescence and cell adhesion assay. KEY FINDINGS: EGCG treatment reduced the activity, protein expression and mRNA expression level of MMP-2. EGCG treatment reduced the expression of focal adhesion kinase (FAK), membrane type-1-matrix metalloproteinase (MT1-MMP), nuclear factor-kappa B (NF-kB), vascular endothelial growth factor (VEGF) and reduced the adhesion of MCF-7 cells to ECM, fibronectin and vitronectin. Real time RT-PCR revealed a reduced expression of integrin receptors alpha5, beta1, alphav and beta3 due to EGCG treatment. SIGNIFICANCE: Down regulation of expression of MT1-MMP, NF-kB, VEGF and disruption of functional status of integrin receptors may indicate decreased MMP-2 activation; low levels of FAK expression might indicate disruption in FAK-induced MMP-2 secretion and decrease in activation of phosphatidyl-inositol-3-kinase (PI-3K), extracellular regulated kinase (ERK) indicates probable hindrance in MMP-2 regulation and induction. We propose EGCG as potential inhibitor of expression and activity of pro-MMP-2 by a process involving multiple regulatory molecules in MCF-7.